A Single Adulteration Limit for Cleaning Validation in a Pharmaceutical Pilot-Plant Environment - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

A Single Adulteration Limit for Cleaning Validation in a Pharmaceutical Pilot-Plant Environment


Pharmaceutical Technology


7. R.J. Forsyth and D. Haynes, "Cleaning Validation in a Pharmaceutical Research Facility," Pharm. Technol. 22 (9), 104–112 (1998).

8. D.G. Dolan et al., "Application of the Threshold of Toxicological Concern Concept to Pharmaceutical Manufacturing Operations," Regul. Toxicol. Pharmacol. 43 (3), 1–9 (2005).

9. R. Baffi et al., "A Total Organic Carbon Analysis Method for Validating Cleaning Between Products in Biopharmaceutical Manufacturing," J. Parenter. Sci. Technol. 45 (1), 13–19 (1991).

10. R.J. Romanach et al., "Combining Efforts to Clean Equipment in Active Pharmaceutical Ingredient Facilities," Pharm. Technol. 23 (1), 46–58 (1999).

11. M.A. Stege et al., "Total Organic Carbon Analysis of Swab Samples for the Cleaning Validation of Bioprocess Fermentation Equipment," BioPharm 9 (4), 42–45 (1996).

12. D.A. LeBlanc, "Establishing Scientifically Justified Acceptance Criteria for Cleaning Validation of Finished Drug Products," Pharm. Technol. 22 (10), 136–148 (1998).

13. FDA, CDER Human Drug CGMP Notes, 6 (2), 5–6 (Rockville, MD, Division of Manufacturing and Product Quality, Office of Compliance, Center for Drug Evaluation and Research, 1998).

14. R.J. Forsyth, V. Van Nostrand, and G. Martin, "Visible Residue Limit for Cleaning Validation and its Potential Application in a Pharmaceutical Research Facility," Pharm. Technol. 28 (10), 58–72 (2004).

15. R.J. Forsyth and V. Van Nostrand, "Application of Visible Residue Limit for Cleaning Validation in a Pharmaceutical Manufacturing Facility," Pharm. Technol. 29 (10), 152–161 (2005).

16. R.J. Forsyth and V. Van Nostrand, "Using Visible Residue Limits for Introducing New Compounds into a Pharmaceutical Research Facility," Pharm. Technol. 29 (4), 134–140 (2005).

17. R.J. Forsyth, J. Hartman, and V. Van Nostrand, "Risk-Management Assessment of Visible-Residue Limits in Cleaning Validation," Pharm. Technol. 30 (9), 104–114 (2006).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here